The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 4 , Pages 991-996.e2 , April 2010

The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer

Presented at the Annual Meeting of the Western Thoracic Surgical Association, Banff, AB, Canada, June 24–27, 2009.

  • Nathaniel R. Evans III, MD

      Affiliations

    • Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass
    • ,
  • Shuang Li, MS

      Affiliations

    • Duke Clinical Research Institute, Duke University, Durham, NC
    • ,
  • Cameron D. Wright, MD

      Affiliations

    • Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass
    • ,
  • Mark S. Allen, MD

      Affiliations

    • Division of Thoracic Surgery, Mayo Clinic, Rochester, Minn
    • ,
  • Henning A. Gaissert, MD

      Affiliations

    • Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass
    • Corresponding Author InformationAddress for reprints: Henning A. Gaissert, MD, Massachusetts General Hospital, Blake 1570, Fruit Street, Boston, MA 02114.

Received 26 June 2009 ,Revised 15 October 2009 ,Accepted 4 November 2009.

References 

  1. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001;72:1149–1154
  2. Roberts JR, Eustis C, Devore R, Carbone D, Choy H, Johnson D. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg. 2001;72:885–888
  3. Venuta F, Anile M, Diso D, Ibrahim M, De Giacomo T, Rolla M, et al. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg. 2007;31:714–717
  4. Wright CD, Gaissert HA, Grab JD, O'Brien SM, Peterson ED, Allen MS. Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. Ann Thorac Surg. 2008;85:1857–1865
  5. Ferguson MK, Gaissert HA, Grab JD, Sheng S. Pulmonary complications after lung resection in the absence of chronic obstructive pulmonary disease–the predictive role of diffusing capacity. J Thorac Cardiovasc Surg. 2009;138:1297–1302Epub 2009 Sep 26
  6. Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright CD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg. 2008;135:247–254
  7. Rosell R, Gomez-Codina J, Camps C, Javier Sanchez J, Maestre J, Padilla J, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer. 1999;26:7–14
  8. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1–6
  9. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer. 2005;49:13–23
  10. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247–253
  11. Mattson KV, Abratt RP, ten Velde G, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol. 2003;14:116–122
  12. Doddoli C, Barlesi F, Trousse D, Robitail S, Yena S, Astoul P, et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg. 2005;130:416–425
  13. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–1892
  14. Albain KS, Scott CB, Rusch VR. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol. 2003;22:621
  15. Robinson LA, Wagner H, Ruckdeschel JC. Treatment of stage IIIA non-small cell lung cancer. Chest. 2003;123:202S–220S

 Disclosures: None.

PII: S0022-5223(09)01684-5

doi: 10.1016/j.jtcvs.2009.11.070

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 4 , Pages 991-996.e2 , April 2010

Article Tools

* Image Usage & Resolution